Getting outpatient treatment for COVID-19

Last updated on April 22, 2022.

Languages available: Español | Tiếng Việt | 中文 | Soomaali | العربية | नेपाली 

Therapeutic Treatments web banner

If you test positive for COVID-19, you may be able to get treatment to help you recover. There are two main types of treatments: monoclonal antibody therapy and antivirals.

If you have mild to moderate symptoms, your symptoms began within the past few days, and you are at risk of getting very sick from COVID-19, call your doctor or health care provider as soon as you can to ask about treatment. If you do not have a provider or health insurance, you can find a place to get treatment using the ASPR COVID-19 Therapeutics Locator or CDPHE’s therapeutics provider map.

Coloradans can use the federal Test to Treat program to seek antiviral treatment. In this program, people can get tested for COVID-19 or present a positive test result, get a prescription for treatment from a health care provider (if appropriate), and have their prescription filled seamlessly. Find a Test to Treat location using ASPR’s COVID-19 Medication Map or CDPHE’s therapeutics provider map. You can also view a list of Colorado’s "Test to Treat” sites.

    Open Embed

    Purple pins = Test to Treat providers
    Blue pins = All other providers


    The therapeutics provider map is updated every Tuesday and Thursday. Providers on this map
    may or may not currently have treatments available. Contact a location directly for more
    information. Talking to a health care provider can help you learn more about whether
    treatment is right for you.

    Monoclonal antibody therapy 

    As of April 5, due to increased COVID-19 cases caused by the omicron BA.2 sub-variant, sotrovimab is no longer authorized by the FDA. Research shows it is unlikely to be effective against BA.2.

    Monoclonal antibody therapy gives you extra antibodies to help fight COVID-19. Your body naturally makes antibodies to fight infection. However, it takes time for your body to make enough antibodies to fight a new virus like COVID-19. Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection—in this case, COVID-19. They help fight the infection faster than your body could do on its own.

    Right now, there are two different types of monoclonal antibody therapies available in Colorado. 

    1. Bebtelovimab is for people who already have COVID-19, have mild to moderate symptoms, are at high risk of getting very sick, and who can’t take other treatments. 

    2. Evusheld is for people who are moderately to severely immunocompromised or who can’t get vaccinated against COVID-19. It can help keep you from getting sick with COVID-19. It isn’t for people who already have COVID-19.

    There are two different ways to get monoclonal antibody therapy in Colorado: 

    1. Talk with your doctor or health care provider. If you are eligible, may provide treatment or can help you find a place to get treatment.

    2. If you do not have a doctor, you can reach out to a health care provider who is offering treatment in Colorado. You can find places to get treatment at The National Infusion Center Association, the ASPR COVID-19 Therapeutics Locator, or CDPHE’s therapeutics map.

    Bebtelovimab is for adults and children (12 years and older who weigh at least 40 kilograms (88 pounds). You may be able to get bebtelovimab if you:

    • Have tested positive for COVID-19.
    • Have had symptoms for seven days or less.
    • Are at high risk for severe COVID-19, including hospitalization or death.
    • Can’t receive other COVID-19 treatment options approved or authorized by the FDA.

    People who are hospitalized due to COVID-19 or require oxygen therapy or respiratory support due to COVID-19 can’t receive monoclonal antibody therapy. If you usually need oxygen therapy or respiratory support for reasons other than COVID-19, and you need an increase in baseline oxygen flow or respiratory support due to COVID-19, you also can’t receive monoclonal antibody therapy.

    People who are sick with certain variants of COVID-19 don’t respond well to bebtelovimab. If you are likely to have a resistant variant, your health care provider may choose to offer you a different kind of therapy.

    Evusheld is available as a preventive treatment for people who are moderately to severely immunocompromised and may not be fully protected after receiving a COVID-19 vaccine. It is also for people who cannot receive a COVID-19 vaccine due to an allergy. Only people who are not currently infected with COVID-19 and have not recently been exposed to COVID-19 can receive Evusheld.

    Evusheld is not a treatment for people who are already infected with COVID-19. It also can’t be used as post-exposure prophylaxis for people who have been exposed to COVID-19.

    • Monoclonal antibody treatment gives you extra antibodies to help fight COVID-19. 

    • Your body naturally makes antibodies to fight infection. However, it takes time for your body to make enough antibodies to fight a new virus like COVID-19. 

    • Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection—in this case, COVID-19. They are given to patients directly with an infusion to help fight the infection faster than your body could do on its own. 

    • Early evidence suggests that monoclonal antibody treatment can reduce the amount of the COVID-19 virus in your system. This amount is called “viral load.” Having a lower viral load means you may have milder symptoms, which may make it less likely that you’ll need to go to the hospital.

    • Depending on what kind of treatment you get, you may receive the therapy through an IV or two injections.

      • Bebtelovimab is given through an IV infusion. This involves placing a needle in a vein and slowly sending the medicine into the body. It may take up to 30 minutes to receive the infusion. 

      • Evusheld is given through two intramuscular injections. This is similar to receiving a vaccine.

    • No matter what kind of treatment you receive, the provider treating you will ask you to stay in the office for one hour after the medication is given to make sure you don’t have an allergic reaction or other side effects that could require medical care. 

    • The whole appointment should last about an hour and a half.

    • Antibody treatments may have side effects. 

    • Allergic reactions can happen during and after an antibody infusion. 

    • Tell your healthcare provider right away if you get any of the following symptoms of allergic reactions: fever; chills; nausea; headache; shortness of breath; low blood pressure; wheezing; swelling of your lips, face, or throat; rash, including hives; itching; muscle aches; and/or dizziness. 

    • An infusion or injection of any medicine may cause brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.

    • Talk to your doctor if you experience any side effect that bothers you or does not go away quickly.

    Antivirals

    Antivirals are medicines that can help treat COVID-19. They can be either pills or IV infusions. 

    As of now, the FDA has authorized three different antivirals under Emergency Use Authorizations.

    1. Paxlovid

      • Paxlovid is a pill for people who have mild or moderate COVID-19 symptoms and are at high risk of getting very sick. People age 12 years or older who weigh at least 40 kilograms (about 88 pounds) can take Paxlovid. It is available by prescription only. 

      • People who are eligible for Paxlovid should receive it as soon as possible after they have been diagnosed with COVID-19, starting within five days of their first symptoms.

    2. Molnupiravir

      • Molnupiravir is a pill for people who have tested positive for COVID-19, are at high risk of getting very sick, and cannot receive other COVID-19 treatments. Only adults age 18 years and older can take molnupiravir. Molnupiravir is available by prescription only. 

      • People who are eligible for molnupiravir should receive it as soon as possible after they have been diagnosed with COVID-19, starting within five days of their first symptoms. 

      • Pregnant people should not take molnupiravir. People who may become pregnant should use effective birth control while they are receiving the treatment and for four days after their last dose.

      • Breastfeeding is not recommended while taking molnupiravir. If you are lactating while taking this treatment, you should pump and discard your breast milk until four days have passed since your last dose.

    3. Remdesivir

      • Remdesivir (Veklury) is an IV infusion for people who have tested positive for COVID-19 and are at high risk of getting very sick. Remdesivir can be given to patients of all ages, including adults and children.

      • People who are eligible for remdesivir should receive it as soon as possible after they have been diagnosed with COVID-19, starting within seven days of their first symptoms.

    • Talk with your doctor or health care provider. Let them know you have tested positive for COVID-19 and want to get antiviral treatment. If you are eligible, your health care provider may be able to help you find a place to get treatment.

    • You can also reach out to a health care provider who is offering treatment in Colorado.

    • Coloradans can also use the new federal Test to Treat program to seek antiviral treatment. In this program, people can get tested for COVID-19, get a prescription for treatment from a health care provider (if appropriate), and have their prescription filled seamlessly (if they are positive and treatments are appropriate).

    • At some Test to Treat locations, people can also bring their own positive result from an at-home test or another testing location. If you are seeking treatment at a King Soopers clinic, you must take your COVID-19 test on-site. You may bring an unopened at-home test to use at your appointment.

    • Find a Test to Treat location using ASPR’s COVID-19 Medication Map or the list below.

    Right now, oral antivirals (Paxlovid and molnupiravir) are authorized for people who:

    • Are age 12 years or older for Pfizer’s Paxlovid or age 18 years or older for Merck’s molnupiravir, and 

    • Have tested positive for COVID-19, and

    • Have had symptoms for less than 5 days, and

    • Are at high risk of becoming seriously ill. People at at high risk of becoming seriously ill from COVID-19 include:

      • People who are 65 years old or older.

      • People who are obese or overweight. This includes adults with a BMI of 25 or more. It also includes children under age 18 years old whose providers determine they meet the criteria.

      • Pregnant people (for Paxlovid only).

      • People with certain underlying medical conditions.

    Right now, the intravenous antiviral remdesivir (Veklury) is authorized or approved for people who:

    • Are adults or are children of any age weighing at least 3.5 kilograms (about 7.7 pounds), and 

    • Have tested positive for COVID-19, and

    • Have had symptoms for less than 7 days, and

    • Are at high risk of becoming seriously ill. People at at high risk of becoming seriously ill from COVID-19 include:

      • People who are 65 years old or older.

      • Infants under 1 year old.

      • People who are obese or overweight. This includes adults with a BMI of 25 or more. It also includes children under age 18 years old whose providers determine they meet the criteria.

      • Pregnant people.

      • People with certain underlying medical conditions.

    See the How Do I Know If I’m High Risk, and What Do I Do Next? page on CombatCOVID.hhs.gov to learn more.

    Antivirals are not a substitute for vaccination against COVID-19. Getting vaccinated is the best way to keep from getting sick with COVID-19. 

    • Paxlovid

      • Paxlovid consists of two different medications taken at the same time. The first is called nirmatrelvir. This medicine stops the COVID-19 virus from copying itself. The second is called ritonavir. Ritonavir helps keep nirmatrelvir from breaking down in the body, helping it work longer.

      • Paxlovid is usually administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Some people with kidney disease may take only two tablets together twice daily for five days, for a total of 20 tablets.

    • Molnupiravir

      • Molnupiravir works by introducing errors into the COVID-19 virus’s genetic code. This prevents the virus from copying itself.

      • Molnupiravir is administered as four capsules taken orally every 12 hours for five days, for a total of 40 capsules.

    • Remdesivir

      • Remdesivir stops the COVID-19 virus from copying itself.

      • Remdesivir is given as an intravenous infusion once a day for three days.

    Paxlovid and molnupiravir are taken for five consecutive days. Remdesivir is used for three days.

    • Paxlovid

      • Possible side effects of Paxlovid include impaired sense of taste, diarrhea, high blood pressure, and muscle aches.

      • Using Paxlovid in people with uncontrolled or undiagnosed HIV-1 infection may lead to HIV-1 drug resistance.

      • Ritonavir may cause liver damage, so caution should be exercised when giving Paxlovid to patients with preexisting liver diseases, liver enzyme abnormalities, or liver inflammation.

      • Using Paxlovid at the same time as certain other drugs may result in potentially significant drug interactions. Find a list of those drugs on Paxlovid’s FDA fact sheet.

      • There is no experience treating pregnant or breastfeeding people with Paxlovid. For a pregnant person and unborn baby, the benefit of taking Paxlovid may be greater than the risk from the treatment. If you are pregnant, discuss your options and specific situation with your health care provider. 

    • Molnupiravir

      • Side effects observed in clinical trials included diarrhea, nausea, and dizziness.

      • Molnupiravir is not recommended for use during pregnancy. Pregnant people should only take molnupiravir if their health care provider decides that the benefits outweigh the risks.

      • People who may become pregnant should use a reliable method of birth control correctly and consistently while taking molnupiravir and for four days after the final dose.

      • If you are sexually active with a partner who might become pregnant, you should use a reliable method of birth control consistently and currently while you are taking molnupiravir and for at least three months after the last dose. 

    • Remdesivir

      • Possible side effects of remdesivir include nausea and abnormal liver tests.

      • Using remdesivir at the same time as certain other drugs may result in decreased effectiveness of remdesivir.

    All Therapeutics Providers with Inventory Available

    This table is only intended to provide information on the current distribution of therapeutics in the state. Patients should contact a health care provider first to  make sure they are eligible for COVID-19 therapeutics.

    Data provided on this page are accurate as of 3 p.m. MST the prior day.

    Populations Served

    The “Pop_Served” column indicates what population the listed provider serves. The general public may not be able to access therapeutics from certain providers depending on the population the facility serves. Where LTCF, DOC or IHS is denoted, these facilities serve only those specific populations.

    Specialized Facility Types (key)

    • LTCF | Long-term care facility
    • DOC | Department of Corrections
    • IHS | Indian Health Service
    Open Embed